Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Konwave ATG Emerging Markets Healthcare Fund A sub-fund of Harrington Cooper UCITS Funds ICAV

Class I USD Accumulating (IE000TFAVGX2)

Manufacturer: Harrington Cooper Asset Management Limited.
The Central Bank of Ireland is responsible for supervising Harrington Cooper Asset Management Limited in relation to this Key Information Document.
This PRIIP is authorised in Ireland.
Harrington Cooper Asset Management Limited is authorised in Ireland and regulated by the Central Bank of Ireland.
For more information on this product, please visit https://harringtoncooper.com/harrington-cooper-asset-management-funds/.

Date of Production 26 June 2026.

What is this product?

Type:
This product is a UCITS Fund. The Fund is a sub-fund of Harrington Cooper UCITS Funds ICAV, an open-ended umbrella Irish collective asset-management vehicle with segregated liability between its sub- funds formed in Ireland under the Irish Collective Asset-management Vehicles Act 2015 and was registered on 12 October 2018. The Fund's assets are held through its Depository, which is Northern Trust Fiduciary Services (Ireland) Limited. Further information in relation to the Fund should be obtained from your financial advisor or distributor or is available at https://harringtoncooper.com/harrington-cooper-asset- management-funds/ in English.

Term:
This Fund is an open-ended UCITS and has an indefinite duration. The Fund may be terminated at any time in line with the constitutional documents of the Company. For full investment objectives and policy details, please refer to the Investment Objectives and Investment Policy in the Fund's Supplement to the Prospectus, which are available at https://harringtoncooper.com/harrington-cooper-asset-management-funds/.

Objectives:
The objective of the Fund is to achieve long-term capital appreciation by investing primarily in equity securities of healthcare companies. The Fund will aim to outperform the Benchmark over rolling three- and five-year periods as part of this objective.

Investment Policy:
The Fund aims to achieve its investment objective by investing a minimum of 80% of its Net Asset Value in equity securities of healthcare companies. The Fund invests primarily across emerging markets (as further detailed below) in healthcare companies including pharmaceuticals, biotechnology, medical technology, and healthcare services as well as related industries including diagnostics companies, life sciences tools companies, digital health companies, specialty pharma companies and clinical research and manufacturing organizations. The Fund typically holds between 30 and 50 individual equity positions.
The Fund follows a disciplined, bottom-up investment approach grounded in a Growth at a Reasonable Price (GARP) philosophy which seeks to combine aspects of growth investing with aspects of value investing. This methodology is applied exclusively to publicly listed small, mid- and large-cap equities within the healthcare sector in developing countries. GARP is an active-type equity investment style which is based on the premise that corporate earnings will be priced in the medium to long term and the rate of return of growth stocks at a reasonable price (i.e. a low valuation) will exceed those of the market. More specifically, the Investment Manager forecasts corporate earnings growth and it is intended that investments will be made in equities with mid-to-long term and above-average growth potential and relatively low valuations gauged by various valuation metrics. The principle valuation metrics are a fundamental analysis of the equity, internal stock ratings and relative attractiveness rankings within the relevant sector.
The Investment Manager seeks to identify healthcare companies that demonstrate robust financial fundamentals, enduring competitive advantages, that are run by experienced and capable management teams, and whose stocks are traded at valuation levels that offer attractive risk-adjusted returns. Risk control is embedded in both security selection and portfolio construction, ensuring a focus on capital preservation as well as upside potential.
The Fund may invest up to a maximum of 20% of the Net Asset Value of the Fund in exchange traded funds (ETFs) covering the Indian healthcare sector in accordance with the requirements of the Central Bank and the investment restrictions set out in Appendix 1 to the Prospectus. With respect to this exposure a maximum of 10% may be invested in a single ETF. The Fund may invest in ETFs for the purpose of managing market exposure in circumstances where material cash flows arise. It is intended that the ETFs in which the Fund may invest will be listed on a Regulated Market.
Cash shall be a residual of the investment process, and it is expected that the Fund will be fully invested at all times. Cash is to be used for ancillary liquidity purposes only and should not exceed 10% of the Net Asset Value of the Fund.
The Fund promotes the following environmental and social characteristics (i) reduction of carbon emissions intensity; and (ii) improved access to healthcare products and services, as further detailed below.
The Fund operates under a long-only mandate and does not invest in FDIs.
The Fund is considered to be actively managed in reference to the Benchmark by virtue of the fact that it seeks to outperform the Benchmark over three and five year periods and the performance fees payable to the Investment Manager are calculated based on the performance of the Fund against the Benchmark. However, the Benchmark is not used to define the portfolio composition of the Fund and the Fund may be wholly invested in securities which are not constituents of the Benchmark. The Benchmark is designed to capture the large, mid and small cap segments across Emerging Market countries. All securities in the Benchmark are classified in the Health Care sector as per the Global Industry Classification Standard (GICS®).

Fund Currency:
The base currency of the Fund is USD.

Income:
The shares will be accumulating. All income will be re-invested.


Subscription and Redemption:

Investors may buy and sell shares on any day on which the retail banks in each of Ireland and the United Kingdom are all generally open for normal banking business. An application must be submitted to the administrator, Northern Trust International Fund Administration Services (Ireland) Limited, by 12 noon (Irish Time) on the business day immediately prior to the business day of the purchase or sale.

Intended retail investor:
The Fund is suitable for any investor (institutional and, unless prohibited by the rules of a particular jurisdiction, retail) seeking to achieve capital appreciation over the long term (i.e., greater than five (5) years). As the Fund invests primarily in equities, investors should consider an investment in the Fund as medium to high risk.

What are the risks and what could I get in return?

Risk Indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the ability for you to receive a positive return on your investment.

Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

For other risks materially relevant to the product which are not taken into account in the summary risk indicator, please read the product's Annual Report or Prospectus available at https://harringtoncooper.com/harrington-cooper-asset-management-funds/.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Performance scenarios

The figures shown include all the costs of the product itself but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

Recommended Holding Period: 5 years

Investment: USD 10,000

Scenarios Minimum: There is no minimum guaranteed return if you exit before 5 years. You could lose some or all of your investment.		If you exit after 1 year	If you exit after 5 years (recommended holding period)
Stress	**What you might get back after costs** Average return each year	**3,760 USD** -62.42%	**2,750 USD** -22.78%
Unfavourable[1]	**What you might get back after costs** Average return each year	**5,690 USD** -43.15%	**6,120 USD** -9.35%
Moderate[2]	**What you might get back after costs** Average return each year	**10,190 USD** 1.92%	**8,900 USD** -2.30%
Favourable[3]	**What you might get back after costs** Average return each year	**15,940 USD** 59.38%	**17,100 USD** 11.32%

[1] This type of scenario occurred for an investment between June 2021 and April 2026.
[2] This type of scenario occurred for an investment between February 2019 and February 2024.
[3] This type of scenario occurred for an investment between May 2016 and May 2021.

What happens if Harrington Cooper Asset Management Limited is unable to pay out?

You may face a financial loss should the manufacturer default on their obligations, there is no compensation or guarantee scheme in place which may offset, all or any of, this loss. The assets of the Fund are held with its Depositary, Northern Trust Fiduciary Services (Ireland) Limited, which is a separate company. Should the Fund default, the Depositary would liquidate the investments and distribute the proceeds to the investors. In the worst case, however, you could lose your entire investment.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed, in the first year you would get back the amount that you invested (0 % annual return). For the other holding period, we have assumed the fund performs as shown in the moderate scenario and the investment is USD 10,000.

Investment: USD 10,000	**If you exit after 1 year**	If you exit after 5 years
Total costs	139 USD	609 USD
Annual cost impact (*)	1.4%	1.4%

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be -0.9% before costs and -2.3% after costs.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	We do not charge an entry fee.	0 USD
Exit costs	We do not charge an exit fee for this product.	0 USD
Ongoing costs taken each year		**If you exit after 1 year**
Management fees and other administrative or operating costs	1.14% of the value of your investment per year. This is an estimate based on actual costs over the last year.	114 USD
Transaction costs	0.25% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	25 USD
Incidental costs taken under specific conditions		**If you exit after 1 year**
Performance fees	This product does not have any performance fees.	0 USD

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

The fund has daily liquidity. The recommended holding period of the Fund assumes the Fund being the sole or majority holding of the investor. The recommended holding period is primarily based on the historic volatility of the underlying investments and is not directly applicable if used in a portfolio based on the investor's risk profile. The Fund is not intended for short term speculation purposes.

How can I complain?

As a shareholder in the Fund, you are entitled to make a complaint free of charge. Any such complaint must be handled by the management company promptly and effectively. You also have the right to refer the relevant complaint to the Financial Services and Pensions Ombudsman after following the Fund's complaints process if you are still not satisfied with the response received. Further information on the complaints policy relating to the Fund is available from the Management Company, Email: Investor@harringtoncooper.com, Address: Harrington Cooper Asset Management Ltd., Block A, One Park Place, Upper Hatch Street, Dublin 2, Ireland

Other relevant information

We are required to provide you with further documentation, such as the product's latest Prospectus, Past Performance and Annual and Semi-annual reports which are available at https://harringtoncooper.com/harrington-cooper-asset-management-funds/ from the Administrator or the Investment Manager in English free of charge. The cost, performance and risk calculations included in this KID follow the methodology prescribed by EU regulation. Past performance for the previous 10 years and historical performance scenarios are available below: https://harringtoncooper.com/ harrington-cooper-asset-management-funds/.

Additional information for investors in Switzerland: the representative in Switzerland is FundRock Switzerland SA, Route de Cité-Ouest 2, 1196 Gland, Switzerland. The paying agent in Banque Cantonale de Genève, 17, quai de l'Ile, 1204 Geneva, Switzerland. In Switzerland, the Prospectus, the Key Information Document, the Articles of Association and the annual and semi-annual reports of the Fund can be obtained free of charge from the representative in Switzerland.